©2024 Stanford Medicine
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
Not Recruiting
Trial ID: NCT02579265
Purpose
To show the superiority in safety of Smoflipid over Intralipid® as measured by the number of
study patients in each treatment group with conjugated bilirubin exceeding 2 mg/dL during the
first 28 days of study treatment, confirmed by a second sample collected 7 days after the
first sample.
Official Title
A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Neonates and infants, expected to require parenteral nutrition (PN) for 28 days
- Postmenstrual age ≥ 24 weeks
- Birth weight ≥ 750g
- Gastroschisis, duodenal, jejunal or ileal atresia, volvulus, spontaneous intestinal
perforation or necrotizing enterocolitis (Bell's stage 2B or higher)
- At least 80% of nutritional needs at baseline received by PN
- Signed and dated informed consent obtained from at least one parent or legal guardian
Exclusion Criteria:
- Conjugated bilirubin > 0.6 mg/dL
- Any known pre-, intra- or posthepatic complication increasing conjugated bilirubin
levels > 0.6, mg/dL during study participation
- Suspected liver disease or liver damage based on either aspartate aminotransferase
(AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) exceeding
2.5x upper limit of normal range
- Active bloodstream infection demonstrated by positive blood culture at screening
- Cystic fibrosis
- Meconium ileus
- Serum triglyceride levels > 250 mg/dL
- Cyanotic congenital heart defect
- Severe renal failure with serum creatinine > 2.0 mg/dL
- History of shock requiring vasopressors
- Anasarca
- Extracorporeal Membrane Oxygenation (ECMO)
- Known inborn errors of metabolism
- Known congenital viral infection
- Unlikely to survive longer than 28 days
- Known hypersensitivity to fish-, egg-, soya- or peanut protein or to any of the active
substances or excipients
Intervention(s):
drug: Smoflipid 20% (investigational lipid for parenteral nutrition)
drug: Intralipid® 20%
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kari McCallie, MD
650-723-5711